The team’s first clue came from combination experiments in living animals. When the researchers paired anti-platelet agents with an antibody that blocks PD-L1—a cornerstone immune checkpoint target exploited by tumors to disarm T cells—they observed a synergistic anti-tumor effect that neither treatment achieved alone. That synergy hinted that platelets were actively contributing to the tumor’s defenses rather than merely bystanders in the tumor microenvironment. When the investigators looked more closely at tumors, they found that activated platelets were adhering directly to tumor-infiltrating CD8-positive T cells. Critically, when platelet activity was suppressed alongside PD-L1 blockade, this adhesion was reduced, and the T cells showed enhanced activation. In other words, stripping platelets away from the immune cells appeared to unleash at least some of the anti-tumor firepower that checkpoint inhibitors are designed to restore.

To determine whether this was a direct cause-and-effect relationship rather than an indirect consequence of the tumor environment, the team built a controlled laboratory system that isolated the players. They used cytotoxic T lymphocytes derived from induced pluripotent stem cells—a line known as CTL3-3—engineered to specifically recognize the WT1 antigen, a protein expressed on many cancer cells and a well-established tumor-associated target. When intact platelets were added to the co-culture of these antigen-specific killer cells and cancer cells, the platelets suppressed the T cells’ cytotoxic activity. The suppression was unmistakable: T cells that would otherwise have efficiently killed their WT1-expressing targets became measurably less lethal in the presence of platelets.

One obvious question was whether platelets were exerting this effect through soluble factors—chemical signals released into the surrounding fluid—rather than through physical contact. To test this, the researchers collected supernatants, the liquid fractions from cultures of activated platelets, and applied them to the T cells. These supernatants did partially suppress cytotoxicity, suggesting that platelet-derived soluble mediators contribute something to the inhibitory effect. But the suppression achieved by soluble factors alone was consistently weaker than the suppression caused by intact platelets. That difference was telling. It implied that the dominant mechanism required the platelets themselves to be physically present, in contact with the T cells, rather than merely whispering chemical instructions from a distance.

Flow cytometry analysis then revealed the nature of that physical contact. Activated platelets express P-selectin, also known as CD62P, a transmembrane adhesion molecule stored in platelet granules and rapidly displayed on the cell surface when platelets are activated. The analysis showed that these P-selectin-bearing platelets directly interact with the CTL3-3 T cells. The team confirmed the interaction with two independent imaging approaches: immunofluorescence staining, which visualized the molecular partners at the interface between the cells, and electron microscopy, which captured the ultrastructural detail of platelets clinging to T cell surfaces. Together, these techniques established that the platelet-T cell adhesion was not an artifact of the assay but a reproducible, physically verifiable phenomenon.

The molecular identity of the T cell-side partner proved to be PSGL-1, the canonical ligand for P-selectin. PSGL-1 is a glycoprotein best known for its role in guiding leukocytes through the bloodstream and into tissues during inflammation, where it engages selectins on vascular endothelial cells. The researchers used neutralizing antibodies to block either P-selectin on the platelets or PSGL-1 on the T cells. Either intervention inhibited the adhesion between the two cell types and, crucially, restored the cytotoxic activity of the T cells in the presence of platelets. This bidirectional blockade experiment is the strongest evidence in the study that the P-selectin–PSGL-1 axis is the functional conduit through which platelets suppress tumor killing. When the handshake is interrupted, the T cells recover their ability to destroy their targets.

Equally important is what the platelets did not do. The researchers found that the interaction suppressed the antigen-specific killing activity of the T cells without affecting their proliferation. The T cells continued to divide and expand normally; they simply became less effective executioners while in contact with platelets. This distinction matters for therapeutic thinking. A mechanism that throttles the cytotoxic function of T cells while leaving their numbers intact suggests a reversible, contact-dependent form of immune regulation—one that could potentially be switched off pharmacologically without causing the broader immune dysfunction that might accompany agents that deplete or globally suppress T cells. It also distinguishes this mechanism from classical checkpoint pathways such as PD-1/PD-L1, which alter T cell activation states through signaling rather than through physical sequestration.

The broader context of this work sits at the intersection of hematology and tumor immunology, a crossroads that has attracted growing attention in recent years. Platelets are known to interact with cancer cells in ways that facilitate tumor progression and enhance malignancy—they shield circulating tumor cells from immune surveillance in the bloodstream, promote metastatic seeding, and release a cargo of growth factors and immunomodulatory molecules. Cancer patients frequently exhibit platelet activation and thrombocytosis, and high platelet counts have been associated with poorer prognosis across multiple tumor types. What has remained murky is the direct effect of platelets on the anti-tumor activity of CD8-positive T cells, the population that immunotherapies from checkpoint inhibitors to engineered T cell therapies ultimately depend upon. By demonstrating a direct, receptor-defined inhibitory interaction, this study fills a conceptual gap and provides a mechanistic explanation for why anti-platelet strategies might synergize with immunotherapy.

The therapeutic implications are tantalizing but must be tempered with caution. The combination of anti-platelet agents and PD-L1 blockade produced synergistic anti-tumor effects in the preclinical setting, and the mechanistic work identifies P-selectin and PSGL-1 as druggable nodes—both are accessible to neutralizing antibodies, and agents targeting the selectin pathway already exist in other clinical contexts. Yet translating these findings into patients will require careful navigation of platelet biology’s essential role in hemostasis. Systemic platelet inhibition carries bleeding risks, and any strategy would need to selectively disrupt the platelet-T cell interaction without compromising clotting. Blocking the P-selectin–PSGL-1 axis specifically, rather than platelet function broadly, may offer a narrower therapeutic window, but this remains to be tested in clinical studies. The current work was conducted in animal models and in vitro systems, and tumor immunology is notorious for promising mechanisms that fail to survive translation.

Nevertheless, the study reframes platelets from passive clotting agents into active participants in the immune battlefield of cancer, and it does so with unusual mechanistic precision—identifying the cell types, the contact dependence, the receptor-ligand pair, and the functional consequence, all within a single coherent experimental arc. For a field racing to explain why immunotherapies work spectacularly in some patients and fail in others, the discovery that activated platelets can handcuff CD8-positive T cells through P-selectin binding offers a new variable to measure, a new biomarker to explore, and a new combination to test. If subsequent studies confirm that the same interaction operates in human tumors and that disrupting it safely enhances checkpoint inhibitor responses, the humble platelet—long celebrated for saving lives one clot at a time—may find itself recast as an accomplice of cancer, and its inhibition as an unexpected weapon in the immunotherapy arsenal.

Subject of Research: The inhibition of CD8-positive T cell anti-tumor activity by platelet P-selectin binding to PSGL-1

Article Title: P-Selectin on activated platelets inhibits the anti-tumor activity of CD8+ T cells through PSGL-1 binding

Article References: Nishiguchi, S., Yokomura, M., Gomibuchi, Y., Nagano, S., Yasunaga, T., Hirohashi, Y., Kawamoto, H., Takagi, S., & Katayama, R. (2026). P-Selectin on activated platelets inhibits the anti-tumor activity of CD8+ T cells through PSGL-1 binding. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04578-7

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04578-7

Keywords: platelets, P-selectin, PSGL-1, CD8-positive T cells, cancer immunotherapy, PD-L1 blockade, WT1 antigen, cytotoxic T lymphocytes, tumor microenvironment, immune checkpoint inhibitors, iPSC-derived T cells, tumor immunology

What distinguishes VISTA from checkpoint molecules such as PD-1 and CTLA-4 is where it acts and how it is deployed. In many human malignancies, VISTA is preferentially enriched not on tumor cells themselves but on the innate immune cells that populate the tumor microenvironment, including tumor-associated macrophages, myeloid-derived suppressor cells and dendritic cells. This compartment-specific distribution matters because these myeloid populations orchestrate much of the immune suppression that characterizes so-called cold tumors. When VISTA is abundant on these cells, the result is suppressive myeloid differentiation, impaired antigen presentation, altered inflammatory cytokine programs and, ultimately, T-cell dysfunction and immune exclusion, the physical and functional exclusion of cytotoxic T lymphocytes from the tumor bed.

The structural biology of VISTA helps explain its unusual behavior. Like PD-L1, it belongs to the B7 family of immunoregulatory molecules, but it possesses distinctive features, including an acidic pH-selective binding mode. Landmark work published in Nature in 2019 demonstrated that VISTA functions as an acidic pH-selective ligand for PSGL-1, meaning its suppressive signaling is most active in the hypoxic, lactate-rich, acidic conditions that prevail inside solid tumors. This pH dependence effectively arms VISTA precisely where tumors are most aggressive and where other therapies struggle, and it may underlie the molecule’s contribution to resistance against PD-1 and CTLA-4 blockade in selected settings.

The receptor web surrounding VISTA extends well beyond PSGL-1. Subsequent studies have identified additional binding partners, including VSIG-3, which inhibits human T-cell function upon engagement, galectin-9, which cooperates with VISTA to suppress cytotoxic T lymphocyte activity, and LRIG1, which engages VISTA on dendritic cells and impairs tumor-specific CD8-positive T-cell responses. A recent study also revealed that a four-amino-acid intracellular motif of VISTA can block growth receptor signaling within cancer cells themselves, indicating that the molecule can exert tumor-intrinsic effects in addition to its immunoregulatory ones. Which of these ligand interactions dominates in living tumors remains an open question and one of the key unresolved issues highlighted by the review authors.

Evidence from preclinical models has been particularly revealing about the myeloid dimension. Research published in Cancer Immunol Res showed that VISTA controls antitumor immunity by regulating myeloid cell-mediated inflammation and immunosuppression, while a 2024 study in Cell Reports demonstrated that VISTA promotes the metabolism and differentiation of myeloid-derived suppressor cells through STAT3- and polyamine-dependent mechanisms. Hypoxia itself induces VISTA expression on myeloid-derived suppressor cells, amplifying their suppressive function. Work on tumor-associated macrophages has shown that VISTA drives these cells toward a pro-tumoral phenotype that promotes cancer cell phagocytosis while down-regulating T-cell responses, and that targeting a conserved population of TIM3-positive, VISTA-positive macrophages can overcome resistance to cancer immunotherapy.

The clinical relevance of this biology is increasingly documented across tumor types. In prostate cancer, VISTA expression was found to increase after ipilimumab therapy, positioning it as a mechanism of adaptive resistance. Comparative analyses of melanoma and pancreatic cancer identified VISTA as a potential target in the notoriously immunotherapy-resistant pancreatic setting, and elevated VISTA has been reported in gastric and colorectal carcinomas, oral squamous cell carcinoma, cervical carcinoma and non-small cell lung cancer. In metastatic melanoma, VISTA upregulation has been linked to acquired resistance to anti-PD-1 therapy. Intriguingly, the prognostic picture is not uniform: in triple-negative breast cancer, VISTA expression on immune cells correlated with favorable outcome, underscoring the review’s central argument that cellular source and spatial localization determine the biological and prognostic meaning of VISTA measurements.

Therapeutic strategies targeting VISTA have advanced into early clinical testing. The oral small-molecule inhibitor CA-170, derived from a PD-1 sequence, exhibited preclinical antitumor efficacy, although debate persists about its precise molecular targets. More refined approaches include KVA12123, a highly potent anti-VISTA antibody described as promising against poorly immunogenic tumors and currently in phase 1/2 testing alone and in combination with pembrolizumab in patients with advanced solid tumors, and HMBD-002, an IgG4 monoclonal antibody evaluated in a first-in-human phase 1 trial. A pH-selective antibody termed SNS-101 has been engineered to activate preferentially in the acidic tumor microenvironment, enhancing PD-1 pathway responses while limiting systemic exposure. Rationally designed antibodies that blockade the C-C’ loop region of VISTA have been shown to reverse immune suppression and remodel the immune microenvironment in an Fc-independent manner.

Combination approaches reflect the conviction that VISTA operates in parallel to, rather than downstream of, classical checkpoints. Bifunctional small molecules simultaneously targeting PD-L1 and VISTA have shown favorable pharmacokinetics in preclinical development, dual silencing of tumor-intrinsic VISTA and CTLA-4 has stimulated T-cell mediated responses in breast cancer models, and VISTA blockade has been shown to enhance the efficacy of radiotherapy in murine melanoma and adenocarcinoma models. Nanoparticle-based delivery systems targeting VISTA have induced potent antitumor immunity in preclinical studies, and chemotherapy itself has been shown to induce VISTA expression in tumor cells via HIF-2alpha, suggesting that sequencing VISTA-directed therapy with cytotoxic treatment could be clinically important.

Technological advances are reshaping how researchers interrogate VISTA biology. Spatial transcriptomics, multiplexed imaging platforms such as CODEX and imaging mass cytometry now allow investigators to map VISTA expression at single-cell resolution within intact tissue architecture, addressing precisely the questions of cellular source and spatial localization that the review identifies as central. Such compartment-resolved analysis may improve prognostic interpretation, biomarker development and patient selection for VISTA-directed therapies, moving the field beyond simple expression quantification toward a functional understanding of where, when and in whom the pathway matters.

The reviewers conclude that VISTA should be regarded as a dynamically regulated, myeloid-centered checkpoint axis rather than a redundant inhibitory receptor, with translational relevance concentrated in checkpoint-refractory and immune-excluded tumors. Whether early pharmacodynamic evidence of target engagement will convert into durable clinical benefit remains the decisive unanswered question, but as combination trials mature and spatial profiling sharpens patient stratification, VISTA is emerging as one of the most compelling next-generation targets in cancer immunotherapy, potentially unlocking treatment for the many patients whom PD-1 and CTLA-4 blockade have so far failed.

Subject of Research: VISTA immune checkpoint biology in myeloid cells and its therapeutic targeting in cancer

Article Title: VISTA as a myeloid-centered checkpoint axis in cancer: biology, tumor microenvironment, and therapeutic implications

Article References: Tekiner, S., Karataş, R. B., Alras, Y., Zıkşahna, K., Merdan, S., & Ihlamur, M. (2026). VISTA as a myeloid-centered checkpoint axis in cancer: biology, tumor microenvironment, and therapeutic implications. Medical Oncology, 43(10), Article 280. https://doi.org/10.1007/s12032-026-03416-1

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03416-1

Keywords: VISTA, VSIR, immune checkpoint, myeloid cells, tumor microenvironment, tumor-associated macrophages, myeloid-derived suppressor cells, cancer immunotherapy, checkpoint resistance, PSGL-1, acidic pH, antibody therapy